Composition for preventing or treating muscle disease comprising centaurea cyanus flower extract

The use of cornflower extract in a composition addresses the lack of effective treatments for muscle diseases by enhancing muscle strength and exercise performance, offering a natural solution for improving muscle weight and function through targeted gene expression and muscle cell differentiation.

WO2024232570A1PCT designated stage expired Publication Date: 2024-11-14KOREA INST OF SCI & TECH
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/005660
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-07-03
Filing Date
2024-04-26
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Current treatments for muscle diseases such as sarcopenia, muscular atrophy, and dystrophy lack effective pharmaceutical solutions, and there is a need for natural products that can improve muscle strength and exercise performance without side effects.

Method used

A composition containing cornflower extract as an active ingredient, which can be used in pharmaceutical, food, or quasi-drug forms, extracted using solvents like water or organic solvents, to increase muscle weight and improve exercise capacity by enhancing gene expression and muscle cell differentiation.

Benefits of technology

The cornflower extract composition effectively increases muscle weight, improves grip strength, and enhances exercise performance by increasing the expression of specific genes related to muscle function and mitochondrial function, with minimal side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024005660_14112024_PF_FP_ABST
    Figure KR2024005660_14112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a composition for preventing, ameliorating or treating a muscle disease, comprising a Centaurea cyanus flower extract. The Centaurea cyanus flower extract of the present invention has the effects of enhancing grip strength, increasing muscle weight, and improving exercise performance and the like. In addition, a composition comprising the Centaurea cyanus flower extract as an active ingredient, according to the present invention, is a natural medicine and can be applied to various products such as pharmaceutical compositions, food compositions and quasi-drug compositions for the prevention, treatment, amelioration or the like of muscle diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Composition for preventing or treating muscle disease containing cornflower extract

[0001] This application claims the benefit of Korean Patent Application No. 10-2023-0061095, filed May 11, 2023, and Korean Patent Application No. 10-2023-0085742, filed July 3, 2023, the entire contents of which are incorporated herein by reference.

[0002] The present invention relates to a composition for preventing or treating muscle disease comprising a cornflower extract.

[0003]

[0004] Muscles are broadly classified into skeletal muscle, cardiac muscle, and visceral muscle. Among them, skeletal muscle is the most abundant tissue in the human body, accounting for 40-45% of body weight. Skeletal muscle is attached to bones through tendons and plays a role in moving or generating force for the bones. A single muscle is composed of numerous muscle fibers, which are in turn made up of numerous myofibrils composed of actin and myosin. When actin and myosin overlap and move, the muscle shortens or lengthens, causing overall muscle contraction and relaxation. An increase in myofibril size means an increase in muscle fiber thickness, which in turn causes muscle growth.

[0005] Muscle diseases progress through a process of weakening skeletal muscles, gradually impairing walking and mobility, making activities of daily living (ADL) difficult and rendering independent living impossible. Furthermore, they can lead to cardiopulmonary dysfunction and other complications, making it crucial to accurately understand the characteristics of each muscle disease and approach it accordingly.

[0006] South Korea entered an aging society in 2000, with the elderly population accounting for 7.2% of the total population. It is predicted that the country will become a super-aged society (over 20%) by 2050 (2013 Elderly Statistics, Statistics Korea). Muscle mass declines with age (approximately 10-15% between ages 50 and 70, and over 30% between ages 70 and 80), leading to a decline in muscle strength and function. This decline is called sarcopenia. Sarcopenia causes impaired mobility and gait, a major factor limiting independent living in older adults. Furthermore, sarcopenia reduces metabolic rate, increases insulin resistance, promotes the development of type 2 diabetes, and increases the risk of hypertension and cardiovascular disease by three to five times. Currently, there are no drugs approved for the treatment of sarcopenia, and drug repositioning technology is under development to apply myostatin inhibitors or existing FDA-approved treatments for other diseases to the treatment of sarcopenia.

[0007] The present inventors have completed the present invention by experimentally confirming that the extract of the cornflower is useful for improving muscle strength and exercise performance as a result of efforts to develop a natural product effective in preventing or treating muscle diseases.

[0008]

[0009] The purpose of the present invention is to provide a pharmaceutical composition for preventing or treating muscle diseases, increasing muscle weight, and / or improving exercise capacity, which contains a cornflower extract as an active ingredient.

[0010] In addition, the purpose of the present invention is to provide a food composition for preventing or improving muscle disease, increasing muscle weight, and / or improving exercise ability, which contains a cornflower extract as an active ingredient.

[0011] The purpose of the present invention is to provide a pharmaceutical composition for preventing or improving muscle disease, increasing muscle weight, and / or improving exercise ability, which contains a cornflower extract as an active ingredient.

[0012] However, the technical problems to be solved by the present invention are not limited to the problems mentioned above, and other problems not mentioned will be clearly understood by those skilled in the art from the description below.

[0013]

[0014] The present invention provides a food composition for preventing or improving muscle disease, increasing muscle weight, and / or improving exercise capacity, which contains a cornflower extract as an active ingredient.

[0015] In addition, the present invention provides a pharmaceutical composition for preventing or improving muscle disease, increasing muscle weight, and / or improving exercise ability, containing a cornflower extract as an active ingredient.

[0016] In addition, the present invention provides a pharmaceutical composition for preventing or treating muscle disease, increasing muscle weight, and / or improving exercise capacity, which contains a cornflower extract as an active ingredient.

[0017] The above muscle disease may be one or more diseases selected from the group consisting of sarcopenia, muscular atrophy, myasthenia, muscular dystrophy, myotonia, hypotonia, muscular weakness, muscular dystrophy, atony, amyotrophic lateral sclerosis, and inflammatory myopathy.

[0018] The above composition can enhance the strength of the teeth.

[0019] The above composition can increase muscle weight.

[0020] The above composition can increase the expression of one or more genes selected from the group consisting of Myd1, Myog, Ppargc1a, UCp3 and Tomm20.

[0021] The above composition can be extracted with a solvent selected from the group consisting of water, organic solvents and mixtures thereof.

[0022] The above organic solvent may be one or more solvents selected from the group consisting of lower alcohols having 1 to 6 carbon atoms, nucleic acids, acetone, ethyl acetate, chloroform, and diethyl ether.

[0023] In addition, the present invention provides a method for preventing, treating, or improving muscle disease, and / or a method for increasing muscle weight, and / or a method for improving exercise capacity, which comprises a step of administering or ingesting to a subject a composition containing a cornflower extract as an active ingredient.

[0024] In addition, the present invention provides a composition containing a cornflower extract as an active ingredient for use in preventing, treating, or improving muscle disease, and / or for use in increasing muscle weight, and / or for use in improving exercise capacity.

[0025]

[0026] The cornflower extract of the present invention has the effect of enhancing grip strength, increasing muscle mass, and improving exercise performance, etc. In addition, the composition comprising the cornflower extract of the present invention as an active ingredient can be applied as a natural medicine to various products such as pharmaceutical compositions, food compositions, and quasi-drug compositions for preventing, treating, or improving muscle diseases.

[0027]

[0028] Figure 1 is a schematic diagram of an animal model design created to confirm the effect of cornflower extract on the treatment or improvement of sarcopenia.

[0029] Figure 2 shows the results confirming the effect of the extract of cornflower on improving grip strength (Con: control group, Dex: Dexamethasone, Oxy: Oxymetholone, CC 100: cornflower extract 100 mg / kg, CC 50: cornflower extract 50 mg / kg, CC 10: cornflower extract 10 mg / kg; ** p <0.01; ***, p <0.001).

[0030] Figure 3 shows the results of confirming the effect of the extract of cornflower on improving exercise performance. a: Maximum running speed, b: Distance run to exhaustion, c: Time taken to exhaustion (Con: control group, Dex: Dexamethasone, Oxy: Oxymetholone, CC 100: 100 mg / kg cornflower extract, CC 50: 50 mg / kg cornflower extract, CC 10: 10 mg / kg cornflower extract; *, p <0.05; ** p <0.01).

[0031] Figure 4 shows the results of confirming the muscle weight increasing effect of the cornflower extract. a: thigh muscle weight, b: hamstring muscle weight, c: calf muscle weight, d: flounder muscle weight (Con: control group, Dex: dexamethasone, Oxy: oxymetholone, CC 100: cornflower extract 100 mg / kg, CC 50: cornflower extract 50 mg / kg, CC 10: cornflower extract 10 mg / kg; *, p <0.05; ** p <0.01; ***, p <0.001).

[0032] Figure 5 shows the results of confirming the effect of the cornflower extract on the survival rate of myotube cells (Con: control group, Dex: Dexamethasone, CC 10: cornflower extract 10 ug / ml, CC 20: cornflower extract 20 ug / ml, CC 40: cornflower extract 40 ug / ml; ***, p <0.001).

[0033] Figure 6 shows the results of confirming the effect of the extract of cornflower on enhancing the expression of muscle cell differentiation markers (Con: control group, Dex: Dexamethasone, CC 10: cornflower extract 10 ug / ml, CC 20: cornflower extract 20 ug / ml, CC 40: cornflower extract 40 ug / ml; *, p <0.05; ** p <0.01).

[0034] Figure 7 shows the results of confirming the effect of the extract of cornflower on enhancing gene expression related to mitochondrial function (exercise performance) (Con: control group, Dex: Dexamethasone, CC 10: cornflower extract 10 ug / ml, CC 20: cornflower extract 20 ug / ml, CC 40: cornflower extract 40 ug / ml; *, p <0.05; ** p <0.01; ***, p <0.001).

[0035]

[0036] The present inventors completed the present invention by experimentally confirming that an extract of cornflower, a natural product with little or no side effects, is effective in increasing the expression of genes related to vascular cell differentiation and exercise performance, increasing muscle weight, and improving exercise performance, etc.

[0037]

[0038] Hereinafter, the present invention will be described in detail.

[0039]

[0040] The present invention provides a composition for preventing, improving or treating muscle disease, increasing muscle weight and / or improving exercise capacity, comprising an extract of Centaurea cyanusa as an active ingredient.

[0041] The above muscle disease may be one or more diseases selected from the group consisting of sarcopenia, muscular atrophy, myasthenia, muscular dystrophy, myotonia, hypotonia, muscular weakness, muscular dystrophy, atony, amyotrophic lateral sclerosis, and inflammatory myopathy.

[0042] The above composition can enhance the strength of the teeth.

[0043] The above composition can increase exercise performance.

[0044] The above composition can increase muscle weight.

[0045] The above composition can increase the expression of one or more genes selected from the group consisting of Myd1, Myog, Ppargc1a, UCp3 and Tomm20.

[0046] The above composition may be a food composition, a health functional food composition, a pharmaceutical composition, or an over-the-counter drug composition.

[0047] In this specification, “prevention” means any action that delays the onset of a muscle disease by administering the composition of the present invention, and “treatment” and “improvement” mean any action that improves or beneficially changes the symptoms of a muscle disease by administering the composition of the present invention.

[0048]

[0049] The above cornflower extract can be extracted using a polar solvent or / and a non-polar solvent.

[0050] The polar solvent may include at least one selected from the group consisting of (i) water, (ii) alcohol (preferably, methanol, ethanol, propanol, butanol, normal-propanol, iso-propanol, normal-butanol, 1-pentanol, 2-butoxyethanol or ethylene glycol), (iii) acetic acid, (iv) dimethyl-formamide (DMFO), and (v) dimethyl sulfoxide (DMSO). The above nonpolar solvent may include at least one selected from the group consisting of acetone, acetonitrile, ethyl acetate, methyl acetate, fluoroalkane, pentane, hexane, 2,2,4-trimethylpentane, decane, cyclohexane, cyclopentane, diisobutylene, 1-pentene, 1-chlorobutane, 1-chloropentane, o-xylene, diisopropyl ether, 2-chloropropane, toluene, 1-chloropropane, chlorobenzene, benzene, diethyl ether, diethyl sulfide, chloroform, dichloromethane, 1,2-dichloroethane, aniline, diethylamine, ether, carbon tetrachloride, and THF.

[0051] More specifically, the extract can be extracted using water, an organic solvent, or a mixture thereof as a solvent, and according to a specific embodiment of the present invention, the extract of the present invention can be obtained by treating water to cornflower.

[0052] The above organic solvent may include one or more solvents selected from the group consisting of lower alcohols having 1 to 6 carbon atoms (methanol, ethanol, propanol, butanol, etc.), hexanes, acetone, ethyl acetate, chloroform, and diethyl ether.

[0053] In addition, the above-mentioned cornflower extract can be prepared into fractions according to a method commonly used in the decomposition of the present technology, and the solvent used to fractionate the above cornflower extract may be at least one selected from the group consisting of water, lower alcohols of C1 to C4, n-hexane, ethyl acetate, acetone, acetonitrile, butyl acetate, 1,3-butylene glycol, methylene chloride, and mixed solvents thereof, but is not limited thereto. However, a butanol fraction may be more preferable.

[0054]

[0055] The term 'extract' used herein has the meaning commonly used in the art as a crude extract as described above, but in a broad sense, it also includes fractions obtained by further fractionation of the extract. That is, the cornflower extract includes not only those obtained using the above-described extraction solvent, but also those obtained by additionally applying a purification process thereto. For example, fractions obtained by passing the extract through an ultrafiltration membrane having a certain molecular weight cut-off value, separation by various chromatographies (designed for separation according to size, charge, hydrophobicity, or affinity), and other additionally performed fractions obtained through various purification methods are also included in the natural product extract of the present invention.

[0056]

[0057] The extract used in the present invention can be manufactured into a powder form by additional processes such as reduced pressure distillation and freeze drying or spray drying.

[0058] Specifically, the extract can be extracted by adding 5 to 50 times the weight of the cornflower of water, an organic solvent, or a mixture thereof, and extracting by adding 10 to 30 times is more preferable, but is not limited thereto. The extraction temperature can be 10 to 150 ℃, and 15 to 120 ℃ is more preferable, but is not limited thereto. The extraction time is preferably 1 to 20 hours, and 2 to 8 hours is more preferable, but is not limited thereto. The extraction method may be any of a cold steeping, an ultrasonic extraction, or a reflux cooling extraction method, but is not limited thereto. The number of extractions is preferably 1 to 5, and 2 to 3 repeated extractions is more preferable, but is not limited thereto. Additionally, the extract can be diluted, concentrated, or purified and dried after being diluted or concentrated before use.

[0059]

[0060] The term "comprising as an active ingredient" in this specification means including a sufficient amount to achieve the efficacy or activity of the cornflower extract. The present invention is a composition extracted from the natural plant material cornflower, and the quantitative upper limit of the cornflower extract included in the composition of the present invention can be selected and implemented within an appropriate range by those skilled in the art.

[0061]

[0062] Pharmaceutical composition for preventing or treating muscle diseases, increasing muscle weight, and / or improving exercise capacity, containing cornflower extract as an active ingredient

[0063] The composition of the present invention can be prepared as a pharmaceutical composition.

[0064] When the composition of the present invention is prepared as a pharmaceutical composition, the pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier.

[0065] According to a preferred embodiment of the present invention, the composition of the present invention may be a pharmaceutical composition comprising (a) a pharmaceutically effective amount of the cornflower extract of the present invention described above; and (b) a pharmaceutically acceptable carrier. The term "pharmaceutically effective amount" as used herein means an amount sufficient to achieve the efficacy or activity of the cornflower extract described above.

[0066] Pharmaceutically acceptable carriers are those commonly used in formulations, and include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. In addition to the above ingredients, the pharmaceutical composition of the present invention may further include lubricants, wetting agents, sweetening agents, flavoring agents, emulsifiers, suspending agents, preservatives, and the like. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995).

[0067] The pharmaceutical composition of the present invention can be administered orally or parenterally.

[0068] The appropriate dosage of the pharmaceutical composition of the present invention can be prescribed in various ways depending on factors such as the formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and reaction sensitivity. The general dosage of the active ingredient included in the pharmaceutical composition of the present invention is within the range of 0.001-100 mg / kg / day, preferably 0.01-35 mg / kg / day, based on adults. Administration may be administered once a day or divided into several times. However, the scope of the present invention is not limited by the above dosage.

[0069] The pharmaceutical composition of the present invention can be manufactured in a unit dosage form or can be manufactured by inserting it into a multi-dose container by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method that can be easily performed by a person having ordinary skill in the art to which the present invention pertains. In this case, the formulation may be in the form of a solution, suspension, syrup or emulsion in an oil or aqueous medium, or in the form of an extract, powder, granule, tablet or capsule, and may additionally include a dispersing agent or stabilizer.

[0070]

[0071] A pharmaceutical composition for preventing or improving muscle disease, increasing muscle weight, and / or improving exercise capacity, containing cornflower extract as an active ingredient

[0072] The composition of the present invention can be provided as a non-pharmaceutical composition.

[0073] The above-mentioned cornflower extract can be added directly or combined with other over-the-counter medications, and can be used appropriately according to conventional methods. The amount of active ingredients mixed can be appropriately determined depending on the intended use (prevention, health, or therapeutic treatment). The above-mentioned over-the-counter medication composition can be used in the manufacture of topical preparations, patches, ointments, and the like, but is not limited thereto.

[0074]

[0075] Food composition for preventing or improving muscle disease, increasing muscle weight, and / or improving exercise capacity, containing cornflower extract as an active ingredient

[0076] The composition of the present invention can be provided as a food composition or a health functional food composition. When the composition containing the cornflower extract of the present invention as an active ingredient is manufactured as a food composition, it includes not only the cornflower extract as an active ingredient, but also ingredients commonly added during food manufacturing, such as proteins, carbohydrates, fats, nutrients, seasonings, and flavoring agents. Examples of the carbohydrates mentioned above include monosaccharides such as glucose, fructose, etc.; disaccharides such as maltose, sucrose, oligosaccharides, etc.; and polysaccharides such as dextrin, cyclodextrin, etc., and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents, natural flavoring agents [thaumatin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.)] and synthetic flavoring agents (saccharin, aspartame, etc.) can be used. For example, when the food composition of the present invention is manufactured into a drink, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, juice, Eucommia extract, jujube extract, licorice extract, etc. may be additionally included in addition to the natural product extract of the present invention.

[0077] The formulation of the above food composition or health functional food composition may be in the form of powder, granules, pills, tablets, capsules, or any other form of general food or beverage.

[0078] There is no particular limitation on the types of the above foods, and examples of foods to which the above substances can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes, and all foods in the conventional sense can be included.

[0079] In general, when manufacturing food or beverages, the cornflower extract may be added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, per 100 parts by weight of the raw material. However, in the case of long-term consumption for health and hygiene purposes or for health control purposes, the amount may be less than the above range. Furthermore, since the present invention utilizes natural substances and thus does not pose any safety issues, it may be used in an amount greater than the above range.

[0080]

[0081] Hereinafter, the present invention will be described in more detail through examples. The objectives, features, and advantages of the present invention will be readily understood through the following examples. The present invention is not limited to the examples described herein and may be embodied in other forms. The examples introduced herein are provided to ensure that those skilled in the art can sufficiently convey the spirit of the present invention. Therefore, the present invention should not be limited by the following examples.

[0082]

[0083] [Manufacturing Example 1] Manufacturing of cornflower extract

[0084] Centaurea cyanus was purchased from Herb Village Co., Ltd., cut into appropriate sizes, and 2 kg of the aerial parts of Centaurea cyanus were added to an extraction vessel with 10 L of water. Cold extraction was performed for 3 days, and the precipitate was removed using a centrifuge. Impurities were filtered out to obtain the filtrate. The solvent was then concentrated under reduced pressure and dried to obtain 290 g of the extract.

[0085]

[0086] [Manufacturing Example 2] Isolation of compounds derived from cornflower extract

[0087] The extract obtained according to Manufacturing Example 1 was subjected to solvent fractionation and then compounds were separated. Specifically, distilled water (10 L x 3 times) was added to the extract of Manufacturing Example 1, and the same amount of butanol was added to separate the butanol layer and the water layer, which were filtered and concentrated under reduced pressure to obtain a butanol fraction (25 g) and a water fraction (260 g). Afterwards, the butanol fraction was separated using a silica gel open column under the condition of MC: MeOH = 15:1-0:15, and separated by molecular weight using a Sephadex open column under the condition of 50% methanol, and 9 compounds were obtained using prep-MPLC.

[0088] Compounds derived from cornflower extract No. Compound 1 (chemical formula 1) Protocatechuic acid 2 (chemical formula 2) Neochlorogenic acid 3 (chemical formula 3) Chlorogenic acid 4 (chemical formula 4) Cryptochlorogenic acid 5 (chemical formula 5) Graveobioside A6 (chemical formula 6) Apiiin 7 (chemical formula 7) Vanillic acid 8 (chemical formula 8) 4-hydroxybenzoic acid 9 (chemical formula 9) Glycine

[0089]

[0090] [Chemical Formula 1]

[0091]

[0092]

[0093] [Chemical Formula 2]

[0094]

[0095]

[0096] [Chemical Formula 3]

[0097]

[0098]

[0099] [Chemical Formula 4]

[0100]

[0101]

[0102] [Chemical Formula 5]

[0103]

[0104]

[0105] [Chemical Formula 6]

[0106]

[0107]

[0108] [Chemical Formula 7]

[0109]

[0110]

[0111] [Chemical Formula 8]

[0112]

[0113]

[0114] [Chemical Formula 9]

[0115]

[0116] [Example 1] Changes in grip strength in mice with sarcopenia induced by dexamethasone administration using cornflower extract

[0117] In order to confirm the therapeutic or improving effect of the cornflower extract prepared in the above-described manufacturing example on sarcopenia, the present inventors created a sarcopenia mouse model, and measured grip strength using control mice and the sarcopenia mouse model.

[0118] The mice used to confirm the efficacy of the cornelian cherry extract were prepared through the following process. As shown in Figure 1, C57BL / 6J mice (male, 12 weeks old) were obtained from Dooyeol Biotech Co., Ltd. and, after a two-week adaptation period, were divided into six test groups (n=10 per group) according to body weight. The diet, administration dose, and administration method administered to the experimental groups are shown in Table 2 below. The test substance was prepared in the form of a liquid suspension using 0.5% CMC and administered for 4 weeks. To compensate for the placebo effect of 0.5% CMC and the weight loss effect due to administration stress, 0.5% CMC was administered orally daily to the vehicle control group. Two weeks after administration of the test substance, the experimental group was administered dexamethasone intraperitoneally for 2 weeks to induce sarcopenia, and the normal control group was administered saline intraperitoneally. All mice were fed the same AIN76 diet (Research Diets) and were administered the test substance for an additional 2 weeks, for a total of 4 weeks. The dark:light cycle was maintained at a 12-hour:12-hour interval, and water was allowed to be consumed ad libitum. As a result of the experiment, as shown in Fig. 2, grip strength decreased over time in the dexamethasone (Dex) group, and grip strength increased in the group of mice fed oxymetholone and cornflower extract, which was the positive control group, compared to the group treated with only dexamethasone (Dex: Dexamethasone, a sarcopenia-inducing substance (25 mg / kg), CC: cornflower extract (10, 50, or 100 mg / kg)).

[0119]

[0120] Test group feed Sarcopenia inducer Oral administration Substance Administration Dose and method Administration period 1 (Con) AIN76 diet Saline Vehicle - 2 weeks Test substance oral administration 2 weeks after test substance and inducer administration (total 4 weeks) 2 (Dex) Dexamethasone (25 mg / kg, once a day, 2 weeks) Vehicle - 3 (Dex + Oxy) Oxymetholone 50 mg / kg, once a day 4 (Dex + CC 100) Cornflower extract 100 mg / kg, once a day 5 (Dex + CC 50) 50 mg / kg, once a day 6 (Dex + CC 10) 10 mg / kg, once a day

[0121]

[0122] [Example 2] Confirmation of the efficacy of improving exercise performance in mice with sarcopenia induced by dexamethasone administration using cornflower extract.

[0123] After the completion of the four-week administration of the cornflower extract in [Example 1] above, exercise performance was evaluated for all administration groups. Specifically, maximum running speed, distance run to exhaustion, and time to exhaustion were evaluated, and the results are shown in Figure 3. As shown in Figure 3, exercise performance was confirmed to have significantly increased in the cornflower extract administration group.

[0124]

[0125] [Example 3] Confirmation of muscle type-specific weight increase in mice with sarcopenia induced by dexamethasone administration using cornflower extract

[0126] After the administration of the cornflower extract for a total of 4 weeks in [Example 1] above, the weight of each type of muscle tissue in all administration groups was confirmed.

[0127] As a result, as shown in Fig. 4, compared to the control group administered saline, the weights of the thigh muscles, hamstring muscles, calf muscles, and soleus muscles were confirmed to decrease in the Dexamethasone administered group, but when the cornflower extract was administered, the weights of these muscles were confirmed to significantly increase.

[0128]

[0129] [Example 4] Effect of cornflower extract on myotube cell viability in C2C12 myotube cells induced by dexamethasone treatment

[0130] Cell culture and differentiation of myoblasts: Myoblasts derived from C2C12 mice (CRL1772; American type cell collection, USA) were cultured in DMEM (Dulbecco's Modified Eagle's Medium) supplemented with 10 (v / v)% FBS, and after reaching 90% confluence, they were transferred to DMEM supplemented with 2 (v / v)% horse serum and cultured for 7 days to differentiate into myotubes.

[0131] After differentiating C2C12 myoblasts into myotubes, myoatrophy was induced by treating the cells with 100 μM of dexamethasone for 24 hours, and the myoatrophy alleviation effect was confirmed by treating with cornflower extract (CC) at concentrations of 10, 20, and 40 ug / ml. As a result, as shown in Fig. 5, it was confirmed that the viability of myotubes decreased by dexamethasone treatment was restored in the extract-treated group.

[0132]

[0133] [Example 5] Effect of Cornflower Extract on Muscle Cell Differentiation and Exercise Performance-Related Gene Expression Enhancement in Dexamethasone-Treated Atrophic C2C12 Myotube Cells

[0134] C2C12 mouse myotubes treated with 10 μM dexamethasone were washed twice with PBS. Total RNA was extracted according to the user-recommended protocol of an RNA extraction kit (GeneAll RNA isolation kit, Seoul, South Korea). cDNA was synthesized from the extracted RNA and subjected to real-time quantitative polymerase chain reaction (RT-qPCR). PCR analysis was performed according to the user-recommended cycling conditions of the analytical instrument (Applied Biosystems 7900 HT thermal cycler, Applied Biosystems). To determine the expression level of each mRNA, beta-actin was used as an endogenous control, and the fold change value compared to the control group was calculated and the relative expression level was compared. The primer sequences are as follows:

[0135] Gene Primer Type Sequence Sequence Number Myd1 Forward CAT AGA CTT GAC AGG CCC CG Sequence Number 1 Reverse CGG GTC CAG GTC CTC AAA AA Sequence Number 2 Myog Forward AGC TAT CCG GTT CCA AAG CC Sequence Number 3 Reverse GCA CAG GAG ACC TTG GTC AG Sequence Number 4 Ppargc1a Forward GTT GCC TGC ATG AGT GTG TG Sequence Number 5 Reverse CAC ATG TCC CAA GCC ATC CA Sequence Number 6 Ucp3 Forward GTT TTG CGG ACC TCC TCA CT Sequence Number 7 Reverse CTC TGT GCG CAC CAT AGT CA Sequence Number 8 Tomm20 Forward TGT GCG GTG TGT TGT CTG TT Sequence Number 9 Reverse TAA GTG CCC AGA GCA CAG GA Sequence Number 10

[0136]

[0137] As a result of the verification, as shown in FIGS. 6 and 7, it was confirmed that the expression of Myd1 and Myog genes, which are muscle cell differentiation markers decreased by dexamethasone treatment, was increased by the treatment with the cornflower extract, and that the expression of Ppargc1a, UCp3, and Tomm20 genes, which are mitochondrial function-related genes (exercise performance markers), was increased by the treatment with the cornflower extract.

Claims

1. A food composition for preventing or improving muscle disease, increasing muscle weight, or improving exercise ability, containing a cornflower extract as an active ingredient.

2. In claim 1, A food composition characterized in that the muscle disease is at least one disease selected from the group consisting of sarcopenia, muscular atrophy, myasthenia, muscular dystrophy, myotonia, hypotonia, muscular weakness, muscular dystrophy, atony, amyotrophic lateral sclerosis, and inflammatory myopathy.

3. In claim 1, A food composition characterized in that the composition has an effect of enhancing malnutrition.

4. In claim 1, The above composition is a food composition characterized in that it increases muscle weight.

5. In claim 1, The above composition is a food composition characterized in that it increases the expression of one or more genes selected from the group consisting of Myd1, Myog, Ppargc1a, Ucp3, and Tomm20.

6. In claim 1, A food composition characterized in that the composition is extracted with a solvent selected from the group consisting of water, organic solvents, and mixtures thereof.

7. In claim 6, A food composition characterized in that the organic solvent is at least one solvent selected from the group consisting of lower alcohols having 1 to 6 carbon atoms, nucleic acids, acetone, ethyl acetate, chloroform, and diethyl ether.

8. A pharmaceutical composition for preventing or improving muscle disease, increasing muscle weight, or improving exercise ability, containing cornflower extract as an active ingredient.

9. A pharmaceutical composition for preventing or treating muscle disease, increasing muscle weight, or improving exercise capacity, containing a cornflower extract as an active ingredient.

10. In claim 9, A pharmaceutical composition characterized in that the muscle disease is at least one disease selected from the group consisting of sarcopenia, muscular atrophy, myasthenia, muscular dystrophy, myotonia, hypotonia, muscular weakness, muscular dystrophy, amyotrophic lateral sclerosis, and inflammatory myopathy.

11. A method for preventing, treating, or improving muscle disease, or a method for increasing muscle weight, or a method for improving exercise capacity, comprising a step of administering or ingesting to a subject a composition containing a cornflower extract as an active ingredient.

12. Use of a composition containing a cornflower extract as an active ingredient for preventing, treating, or improving muscle disease, or for increasing muscle weight, or for improving exercise ability.

Citation Information

Patent Citations

  • Composition with stimulating effect, comprising the extract of medicinal plants

    KR1020130000664A

  • Use of cichorium intybus extract for preventing, curing, and treating muscle damaging

    KR1020140000767A

  • Composition comprising 3,5-dicaffeoylquinic acid or extract of chrysanthemum as an effective ingredient for preventing or treating of muscular disorder or improvement of muscular functions

    KR1020180079174A

  • Apparatus for expanding network and method for expanding network using the same

    KR1020210015451A

  • Electronic apparatus for managing order and method thereof

    KR1020230164915A